Revolution Medicines stock
RVMDNASDAQRevolution Medicines, Inc., HealthcareISIN US76155X1000
41Score 41 out of 100, Weak
Price and trend
64 / 100
Price history
+168% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since October 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 20% below its 52-week high. Largest decline in 7 years: 73% (February 2021 to May 2022).
Chart figures for advanced users
- SMA 50$195.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$159.51
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$64.38
- The lowest closing price of the last twelve months.
- Resistance$221.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Revolution Medicines, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $38.14B, is number 9 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 41 out of 100 (Weak): rank 534 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $3.65B, financial debt $639.1M.Stability 54
Weaknesses
- DilutionShare count up 185% since 2020.Capital allocation 18
- Loss-makingLoss of $1.87B over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$1.44B over the last 12 months.Fundamentals 17
Its standout strength is momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 43 to 41.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 4 Nov 2026EPS reported −$1.90 (expected −$2.35)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 48.4% since 15 Oct 2026.
- Earnings per share
- −$8.51+10.3%
- Revenue
- $568.29M+181.9%
- Earnings per share
- −$2.95+48.4%
- Revenue
- $2B+62.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.2%2026 GAAP operating expenses updated to $2.1 billion to $2.2 billion; enrollment in a lung cancer study is to complete this year, with an initial readout expected in 2027.
“The company is updating its projected 2026 GAAP operating expense expectations and now expects full year 2026 GAAP operating expenses to be between $2.1 billion and $2.2 billion.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 10 insiders sold, $103.09M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Mancini AnthonySale
9 Nov 2026, See Remarks
- Shares
- 811
- Price
- $200.00
- Value
- $162,200
- Mancini AnthonySale
26 Oct 2026, See Remarks
- Shares
- 2,310
- Price
- $186.99
- Value
- $431,947
- Sandler Alan B.Sale
29 Sept 2026, Chief Development Officer
- Shares
- 6,309
- Price
- $202.14
- Value
- $1.28M
Show 29 more
- Cislini JeffSale
25 Sept 2026, SVP & General Counsel
- Shares
- 765
- Price
- $207.32
- Value
- $158,600
- Mancini AnthonySale
25 Sept 2026, See Remarks
- Shares
- 3,121
- Price
- $200.54
- Value
- $625,885
- Mancini AnthonySale
24 Sept 2026, See Remarks
- Shares
- 587
- Price
- $200.00
- Value
- $117,400
- Anderson Elizabeth MSale
22 Sept 2026, Board
- Shares
- 10,143
- Price
- $193.04
- Value
- $1.96M
- Mancini AnthonySale
18 Sept 2026, See Remarks
- Shares
- 1,764
- Price
- $196.94
- Value
- $347,402
- Sandler Alan B.Sale
16 Sept 2026, Chief Development Officer
- Shares
- 341
- Price
- $199.24
- Value
- $67,941
- Mancini AnthonySale
16 Sept 2026, See Remarks
- Shares
- 1,774
- Price
- $199.24
- Value
- $353,449
- Kelsey Stephen MichaelSale
16 Sept 2026, See Remarks
- Shares
- 5,569
- Price
- $199.24
- Value
- $1.11M
- Horn Margaret ASale
16 Sept 2026, Chief Operating Officer
- Shares
- 4,967
- Price
- $199.24
- Value
- $989,613
- Goldsmith Mark ASale
16 Sept 2026, See Remarks
- Shares
- 13,988
- Price
- $199.24
- Value
- $2.79M
- Cislini JeffSale
16 Sept 2026, SVP & General Counsel
- Shares
- 3,366
- Price
- $199.24
- Value
- $670,631
- Anders JackSale
16 Sept 2026, Chief Financial Officer
- Shares
- 4,053
- Price
- $199.24
- Value
- $807,513
- Kelsey Stephen MichaelSale
11 Sept 2026, See Remarks
- Shares
- 92,531
- Price
- $202.36
- Value
- $18.72M
- Mancini AnthonySale
10 Sept 2026, See Remarks
- Shares
- 15,448
- Price
- $204.16
- Value
- $3.15M
- Kim Lorence H.Sale
8 Sept 2026, Board
- Shares
- 17,090
- Price
- $209.82
- Value
- $3.59M
- Kim Lorence H.Sale
31 Aug 2026, Board
- Shares
- 56,000
- Price
- $203.24
- Value
- $11.38M
- Cislini JeffSale
21 Aug 2026, General Counsel
- Shares
- 56,894
- Price
- $209.24
- Value
- $11.9M
- Goldsmith Mark ASale
21 Aug 2026, See Remarks
- Shares
- 86,000
- Price
- $209.20
- Value
- $17.99M
- Patel SushilSale
29 Jun 2026, Board
- Shares
- 5,580
- Price
- $187.99
- Value
- $1.05M
- Anders JackSale
24 Jun 2026, Chief Financial Officer
- Shares
- 20,000
- Price
- $168.33
- Value
- $3.37M
- Horn Margaret ASale
17 Jun 2026, Chief Operating Officer
- Shares
- 29,600
- Price
- $160.12
- Value
- $4.74M
- Mancini AnthonySale
16 Jun 2026, See Remarks
- Shares
- 4,615
- Price
- $156.12
- Value
- $720,490
- Goldsmith Mark ASale
16 Jun 2026, See Remarks
- Shares
- 10,020
- Price
- $156.12
- Value
- $1.56M
- Cislini JeffSale
16 Jun 2026, General Counsel
- Shares
- 2,157
- Price
- $156.12
- Value
- $336,749
- Anders JackSale
16 Jun 2026, Chief Financial Officer
- Shares
- 2,722
- Price
- $156.12
- Value
- $424,956
- Kelsey Stephen MichaelSale
16 Jun 2026, See Remarks
- Shares
- 4,175
- Price
- $156.12
- Value
- $651,798
- Horn Margaret ASale
15 Jun 2026, Chief Operating Officer
- Shares
- 60,400
- Price
- $160.17
- Value
- $9.67M
- Horn Margaret ASale
11 Jun 2026, Chief Operating Officer
- Shares
- 10,000
- Price
- $148.01
- Value
- $1.48M
- Mancini AnthonySale
26 May 2026, See Remarks
- Shares
- 3,121
- Price
- $153.99
- Value
- $480,611
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Revolution Medicines
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- argenxARGX $61.78B70
- Lonza GroupLONN.SW $55.83B63
- Samsung Biologics207940.KS $50.56B68
- BeOne MedicinesONC $44.45B70
- Celltrion068270.KS $35.82B64
- GenmabGMAB.CO $32.18B66
- Roivant SciencesROIV $28.98B48
- InsmedINSM $25.9B43
ETFs that hold Revolution Medicines
Held by 71 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 3.69% | 0.89% | €11.72M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 2.50% | 0.35% | €1.25B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 2.11% | 0.25% | €45.16M |
Show 5 more
| HAN-GINS Tech Megatrend Equal Weight UCITS ETF AccT3KE | 0.75% | 0.59% | €98.84M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.45% | 0.12% | €1.39B |
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.44% | 0.20% | €272.21M |
| Deka MSCI USA MC UCITS ETFEL41 | 0.41% | 0.30% | €52.63M |
| iShares MSCI World Momentum Factor Advanced UCITS ETFCBUH | 0.36% | 0.25% | €267.4M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.